MARKET

HGEN

HGEN

Humanigen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.140
-0.120
-5.31%
After Hours: 2.170 +0.03 +1.40% 17:32 05/23 EDT
OPEN
2.490
PREV CLOSE
2.260
HIGH
2.490
LOW
2.115
VOLUME
1.66M
TURNOVER
0
52 WEEK HIGH
23.53
52 WEEK LOW
1.670
MARKET CAP
151.16M
P/E (TTM)
-0.6728
1D
5D
1M
3M
1Y
5Y
INO, WWR and CTIC among pre market gainers
GeoVax Labs (GOVX) +20%. Inovio Pharmaceuticals (INO) +19%. SIGA Technologies (SIGA) +15% Monkeypox plays indicate further upside as global toll climbs. O2Micro International (OIIM) +13%. GoldMining (GLDG) +12%. Emergent BioSolutions (EBS) +12% Monkeypox p...
Seekingalpha · 16h ago
24 Stocks Moving in Monday's Pre-Market Session
Gainers Genocea Biosciences, Inc. (NASDAQ: GNCA) shares rose 33.8% to $0.2795 in pre-market trading after declining around 5% on Friday.
Benzinga · 19h ago
Insider Buy: Humanigen
MT Newswires · 22h ago
38 Stocks Moving In Thursday's Mid-Day Session
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares climbed 34.6% to $4.1993 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia.
Benzinga · 4d ago
Humanigen: A ‘Transformative Year’ Awaits, Says Analyst
Accounting for many stocks losing a huge chunk of their valuations in 2022’s inhospitable stock market, analysts have been busy slashing estimates and price targets this year. However, for H.C. Wainwright analyst Joseph Pantginis, there has been no such ch...
TipRanks · 05/12 00:43
92 Biggest Movers From Friday
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the commercialization of space technologies and services.
Benzinga · 05/09 10:27
Investors in Humanigen (NASDAQ:HGEN) from a year ago are still down 89%, even after 14% gain this past week
It's nice to see the Humanigen, Inc. ( NASDAQ:HGEN ) share price up 14% in a week. But that doesn't change the fact...
Simply Wall St. · 05/09 10:15
Humanigen GAAP EPS of -$0.32 beats by $0.14, revenue of $1.04M beats by $0.83M
Humanigen press release (NASDAQ:HGEN): Q1 GAAP EPS of -$0.32 beats by $0.14. Revenue of $1.04M (+112.2% Y/Y) beats by $0.83M. Shares +1.09% AH.
Seekingalpha · 05/05 21:49
More
No Data
Learn about the latest financial forecast of HGEN. Analyze the recent business situations of Humanigen Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

14.29%Strong Buy
42.86%Buy
28.57%Hold
14.29%Under-perform
0.00%Sell
Analyst Price Target
The average HGEN stock price target is 16.43 with a high estimate of 30.00 and a low estimate of 3.000.
High30.00
Average16.43
Low3.000
Current 2.140
EPS
Actual
Estimate
-0.96-0.72-0.48-0.24
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 93
Institutional Holdings: 30.26M
% Owned: 42.84%
Shares Outstanding: 70.63M
TypeInstitutionsShares
Increased
37
7.32M
New
21
2.96M
Decreased
21
9.32M
Sold Out
16
773.78K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.75%
Pharmaceuticals & Medical Research
+0.70%
Key Executives
Chairman/Chief Executive Officer/Director
Cameron Durrant
Chief Financial Officer/Chief Operating Officer
Timothy Morris
Chief Scientific Officer/Director
Dale Chappell
Other
Edward Jordan
Other
Adrian Kilcoyne
Independent Director
Ronald Barliant
Independent Director
Rainer Boehm
Independent Director
Cheryl Buxton
Independent Director
John Hohneker
Independent Director
Y. Kevin Xie
No Data
No Data
About HGEN
Humanigen, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing immuno-oncology and immunology monoclonal antibodies. The Company’s Humaneered technology platform offers a method for converting existing antibodies into engineered human antibodies designed for therapeutic use, primarily for chronic conditions. It is focused on development of lead product candidate lenzilumab, a Humaneered anti-human granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody. Lenzilumab is a monoclonal antibody designed to target and neutralize human GM-CSF and prevents outcomes related to COVID-19. It is also developing lenzilumab as a treatment for autoimmune and other inflammatory conditions, including eosinophilic asthma, rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), inflammatory bowel disease (IBD), juvenile idiopathic arthritis (JIA), atopic dermatitis (AD) and systemic lupus erythematosus (SLE).

Webull offers kinds of Humanigen Inc stock information, including NASDAQ:HGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HGEN stock methods without spending real money on the virtual paper trading platform.